The meeting will highlight bispecific antibodies and "off the shelf" CAR T-cell therapies, potentially transforming treatment paradigms. Fixed-duration therapies are gaining attention for their ...
Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025
People come to Orlando, Florida to escape. With Disney World, SeaWorld and Universal Studios all in the area, there are endless opportunities to leave behind the challenges of the real world for a bit ...
As a hematologist with a keen interest in multiple myeloma who’s looking forward to the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in December, I’ve picked out this list ...
The American Society of Hematology’s annual meeting draws tens of thousands of medical professionals from around the world. And for good reason — some of the most groundbreaking research into diseases ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology ...
Anticipating the 2025 American Society of Hematology Annual Meeting and Exposition, Suchitra Sundaram, MD, reviews several clinical trials in chronic lymphocytic leukemia (CLL) that will present data ...
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...
Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results